Guardant Health Gives Its Two Co-CEOs 465,413 Stock Units Each, Payable Only If They Beat The S&P 500

The awards pay nothing below the 40th percentile of relative shareholder return and top out at 250% of target.

Share
Guardant Health Gives Its Two Co-CEOs 465,413 Stock Units Each, Payable Only If They Beat The S&P 500

Guardant Health, which makes blood and tissue tests for cancer, gave each of its founders and Co-CEOs, Helmy Eltoukhy and AmirAli Talasaz, a 465,413-unit performance stock award that pays out only if the stock's total return beats S&P 500 companies. The company's independent directors approved the grants Monday, according to an 8-K filed Tuesday.

How the payout scale works

Each grant is 465,413 restricted stock units at target, issued under the 2018 Incentive Award Plan. Of those, 25% can be earned on relative shareholder return from June 1, 2026 to May 31, 2029, and the other 75% over June 1, 2026 to May 31, 2031.

Nothing is earned below the 40th percentile of the S&P 500 constituents. The award pays 50% of target at the 40th percentile, 100% at the 55th, 150% at the 75th and a maximum of 250% at the 90th or higher, with straight-line interpolation in between.

If the company's own shareholder return is negative over a period, the payout is capped at 100% of target however well it ranks. Unearned three-year units can carry into the five-year period, but only if five-year relative performance reaches the 75th percentile.

Earned units vest when the Compensation Committee certifies results. Shares from the three-year units generally can't be transferred until May 31, 2030, and half of the net after-tax shares from the five-year units are locked until November 30, 2031.

A 275% return behind the grant

The board pointed to a 275% total shareholder return over the last three fiscal years under the two leaders, which it said beat the Nasdaq Biotechnology, Russell 3000 and S&P 500 indices. It said their continued leadership is critical as the company scales commercially and pushes an "aggressive multi-year pipeline of new products and enhancements."

The board said it worked with an independent compensation consultant on market benchmarks in designing the awards, which it describes as 100% performance-based.

Exits and change in control

If a Co-CEO is fired without cause or quits for good reason, a pro-rated share of target can still vest based on performance through the termination date. Death or disability vests target for the period. Any other departure forfeits unvested units.

In a change in control, units are deemed earned at the greater of target or actual performance, pro-rated if the deal happens on or before May 31, 2027. If the acquirer doesn't assume the awards they vest immediately; if it does, they convert to time-based vesting on May 31, 2029 or May 31, 2031.

Guardant's products include Guardant360 for advanced cancer, Reveal for residual disease and the Shield blood screening test for colorectal cancer.

The Compensation Committee will certify the first three-year results after the period ends May 31, 2029.

Sources